Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake (GATE)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The aim of this study is to elucidate whether GLP-1 analogues influence not only appetite but also thirst perception. It is hypothesized that GLP-1 analogues reduce fluid intake in healthy volunteers compared to Placebo.
Full description
GLP-1 analogues are well known to stimulate glucose-induced insulin secretion and to reduce energy intake. Recent findings from animal and human studies suggest a role of GLP-1 in regulating water and salt homeostasis. GLP-1 has been shown to reduce fluid intake after an oral salt load or during a meal - pointing to a hypodipsic effect. The aim of this study is to elucidate whether these putative hypodipsic properties of GLP-1 analogues reduce fluid intake in healthy volunteers compared to placebo assessed during an evaluation visit of 8 hours.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age 18 to 65 years
Exclusion criteria
- Known or probable central or nephrogenic Diabetes insipidus, based on patient's history
- Polyuria secondary to diabetes mellitus, hypokalemia, hypercalcemia
- Primary Polydipsia, defined as more than 4 liters fluid intake per day
- BMI <18 or >30kg/m2
- Pregnancy
- Previous treatment with GLP-1 agonists within the last 3 month
- History of pancreatitis
- Severe renal insufficiency (eGFR (CKD EPI) <30 ml/min/1,73 m2)
- Cancer
Trial design
Primary purpose
Allocation
Interventional model
Masking
17 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal